182 related articles for article (PubMed ID: 11573800)
1. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
[TBL] [Abstract][Full Text] [Related]
2. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
3. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
4. An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.
McDevitt MR; Finn RD; Sgouros G; Ma D; Scheinberg DA
Appl Radiat Isot; 1999 May; 50(5):895-904. PubMed ID: 10214708
[TBL] [Abstract][Full Text] [Related]
5. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Oct; 55(4):463-70. PubMed ID: 11545498
[TBL] [Abstract][Full Text] [Related]
6. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
[TBL] [Abstract][Full Text] [Related]
7. An Overview of Targeted Alpha Therapy with
Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
Kennel SJ; Chappell LL; Dadachova K; Brechbiel MW; Lankford TK; Davis IA; Stabin M; Mirzadeh S
Cancer Biother Radiopharm; 2000 Jun; 15(3):235-44. PubMed ID: 10941530
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 225Ac radioimmunopharmaceuticals.
McDevitt MR; Ma D; Simon J; Frank RK; Scheinberg DA
Appl Radiat Isot; 2002 Dec; 57(6):841-7. PubMed ID: 12406626
[TBL] [Abstract][Full Text] [Related]
10. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.
Kaspersen FM; Bos E; Doornmalen AV; Geerlings MW; Apostolidis C; Molinet R
Nucl Med Commun; 1995 Jun; 16(6):468-76. PubMed ID: 7675360
[TBL] [Abstract][Full Text] [Related]
12. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Dhiman D; Vatsa R; Sood A
Nucl Med Commun; 2022 Sep; 43(9):970-977. PubMed ID: 35950353
[TBL] [Abstract][Full Text] [Related]
13. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.
Geerlings MW; Kaspersen FM; Apostolidis C; van der Hout R
Nucl Med Commun; 1993 Feb; 14(2):121-5. PubMed ID: 8429990
[TBL] [Abstract][Full Text] [Related]
14. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
17. The Production of Ac-225.
Engle JW
Curr Radiopharm; 2018; 11(3):173-179. PubMed ID: 29669509
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
[TBL] [Abstract][Full Text] [Related]
19. Targeted alpha therapy with 213Bi.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
[TBL] [Abstract][Full Text] [Related]
20. NorthStar Perspectives for Actinium-225 Production at Commercial Scale.
Harvey JT
Curr Radiopharm; 2018; 11(3):180-191. PubMed ID: 29766832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
